Biotech ETFs: A Good Bet Beyond Novel Coronavirus

The battle against COVID-19 has fueled serious upside for an array of healthcare assets this year.  And within health care, there is perhaps no subsector more exciting than biotechnology.  That is the use of living systems and organisms in health applications.  Biotechnology can be used in a host of treatments, including applications such as the insulin taken by diabetics as well as dynamic cancer therapies that stimulate the body’s own immune system to fight off the disease.  

Vaccine-makers like Moderna and Pfizer may be in the spotlight now, but beyond novel coronavirus, investors are drawn to biotech because it is one of the most innovative components of the broader healthcare sector, and that innovation fuels growth.

According to Morningstar:

“We project 4.7% annual  average sales growth through 2024 for the 18 moatiest pharma and biotech names we cover, as innovation more than counters generic/ biosimilar and branded competitive threats.”

As you can imagine, the universe of biotechnology stocks is as vast as the potential treatments in the field, so a diversified exchange-traded fund may be very appealing to investors who want exposure to this sector while avoiding some of the risk and volatility associated with investing in an individual company.  

Let’s explore two different biotech ETFs.  One has heavier allocations towards companies who are skyrocketing on vaccine progress.  The other isn’t heavy on Coronavirus fighters, but it’s highly relevant in the current biotech environment and beyond.  

iShares Nasdaq Biotechnology ETF (NASDAQ: IBB)

The IBB fund seeks to track the investment results of the NASDAQ Biotechnology Index composed of biotechnology and pharmaceutical equities listed on the NASDAQ Stock Market.  The Fund invests at least 90% of its assets in securities of the underlying Index and in depositary receipts representing securities of the Index.

  • $10.43 billion in assets under management
  • Among IBB’s top holdings are Biogen, Moderna, Regeneron Pharmaceuticals Inc. and Gilead Inc. 
  •  Share price for IBB is up 30%% for the past twelve months.  
  • 0.47% expense ratio
  • price/book ratio 5.87
  • 0.096% dividend yield

ALPS Medical Breakthrough ETF (NYSEARCA: SBIO)

This Fund seeks investment results that correspond generally to the performance of the Poliwogg Medical Breakthroughs Index.  The index is comprised of small and mid cap stocks of biotech and pharmaceutical companies that have one or more drugs in either Phase II or Phase III U.S. FDA trials.  

SBIO may not have heavy allocations in COVID fighters, but the pandemic is placing added emphasis on later stage clinical trials- good for SBIO.  Another relevant trait of SBIO – its member firms must have enough cash to survive at least 24 months at current burn rates.

  • $264 million in assets under managemet
  • SBIO top holdings include Kodiak Sciences, Principa Biopharma Inc., Karuna Therapeutics Inc. and Dicerna Pharmaceuticals Inc.  
  • Share price is up 30% for the past twelve months
  • Price/ Book ratio 5.59
  • 0.50% expense ratio
  • 0.40% Yield

Of course, compared to other biotech investments, a less risky ETF investment probably won’t provide exponential returns in the near term.  

To our readers who are seeking an opportunity to ride the crest of the next biotech revolution — we have another recommendation for you.  A breakthrough that could generate $15 trillion in new wealth over the next five years. 

When this tiny company reveals it’s indisputable findings, it’s poised to unleash a $15 trillion tidal wave of new money. This means the small firm’s share price could soar by 311,478% and turn every $500 that you put down into more than $1.5 million.  

Jeff Bezos, Peter Theil, the Rockefellers, the Mayo Clinic, the world’s top doctors, and the most brilliant biomedical entrepreneurs have all been funneling hundreds of millions of dollars into this small biotech firm ahead of this early trial data…

Do you think they have an idea of what’s coming?   

They’re all getting ready for what citibank is calling “the greatest wealth building event in history,” and it’s about to unfold.

Click here to find out which biotech breakthrough could change the course of history, and how you can get involved.   

Where to invest $1,000 right now...

Before you consider buying SBIO, you'll want to see this.

Investing legend, Keith Kohl just revealed his #1 stock for 2022...

And it's not SBIO.

Jeff Bezos, Peter Thiel, and the Rockefellers are betting a colossal nine figures on this tiny company that trades publicly for $5.

Keith say’s he thinks investors will be able to turn a small $50 stake into $150,000.

Find that to be extraordinary?

Click here to watch his presentation, and decide for yourself...

But you have to act now, because a catalyst coming in a few weeks is set to take this company mainstream... And by then, it could be too late.

Click here to find out the name and ticker of Keith's #1 pick...